Antibiotic specialist Paratek Pharmaceuticals (NSDQ:PRTK) recently shared new data related to its tetracycline-class antibacterial Nuzyra (omadacycline).
Specifically, the company provided real-world data related to pneumonia, skin infections and nontuberculous mycobacterial infections in presentations at IDWeek 2021, a virtual conference organized by several infectious disease associations. The company also has collected data on in vitro activity related to B. anthracis, the bacterium that causes anthrax.
“With these presentations, Paratek continues to deepen the understanding of the utility of Nuzyra for serious community-acquired infections and nontuberculous mycobacterial infections, a rare disease for which there are no approved therapies,” said Randy Brenner, chief development & regulatory officer of Paratek, in a statement. “Notably, we will share the results of two studies examining the potential of Nuzyra in treating anthrax infections, one of the agents most likely to be used in a bioterrorism attack, and a health economics study examining healthcare resource utilization among patients treated with Nuzyra for skin infections and pneumonia.”
Last month, the company announced that the FDA granted the company orphan drug designation for Nuzyra to nontuberculous mycobacteria infections.
Filed Under: Infectious Disease